The combination of a MEK inhibitor with a CDK4/6 inhibitor was synergistic in preclinical models of neuroblastoma [11], resulting in the initiation of a phase I clinical trial (NCT02780128). This evidence concerns the gene MAP2K7 and neuroblastoma.